Literature DB >> 19709102

Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?

R Meys1, F M Gotch, C B Bunker.   

Abstract

Human immunodeficiency virus (HIV)-related cutaneous and anogenital disease in the highly active antiretroviral therapy (HAART) era presents challenging problems for dermatologists. Immune reconstitution-associated diseases (IRADs) are common and important consequences of HAART. Dermatologists should be aware of the cutaneous manifestations of IRAD. The prevalence of clinical human papillomavirus (HPV)-related disease is increased in HIV and does not appear to be diminished by HAART. Many patients on HAART are dogged by persistent cutaneous warts. Anogenital precancer is also common in HIV and may be burgeoning with HAART. Clinicians should be aware of the increased risk of cervical, penile and vulval/vaginal cancers in treated and untreated patients with HIV. The increase in HPV infection in HIV-infected individuals may be, at least partly, due to increased exposure to diverse HPV types, particularly high-risk types that might be able to persist for longer in anogenital regions. Alternatively, persistent/emergent HPV disease in HIV infection might represent persistent or modulated immunodysregulation after HAART and be viewed as a form of IRAD. The immunopathogenesis of HPV IRAD is fascinating and possibly determined by host genotype.

Entities:  

Mesh:

Year:  2009        PMID: 19709102     DOI: 10.1111/j.1365-2133.2009.09365.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Mechanisms of viral infections associated with HIV: workshop 2B.

Authors:  S M Tugizov; J Y Webster-Cyriaque; S Syrianen; A Chattopadyay; H Sroussi; L Zhang; A Kaushal
Journal:  Adv Dent Res       Date:  2011-04

Review 2.  Interventions for anal canal intraepithelial neoplasia.

Authors:  Antonio Macaya; Carlos Muñoz-Santos; Albert Balaguer; Maria Jesús Barberà
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  HIV protease inhibitors alter innate immune response signaling to double-stranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome?

Authors:  Robert J Danaher; Charlotte S Kaetzel; Richard N Greenberg; Chunmei Wang; Maria E C Bruno; Craig S Miller
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

4.  Pattern of skin disease in Ethiopian HIV-infected patients on combination antiretroviral therapy: A cross-sectional study in a dermatology referral hospital.

Authors:  F Shikur; H Yeung; W Amogne; R Weller
Journal:  Skin Health Dis       Date:  2021-05-03

5.  Influence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa.

Authors:  R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes
Journal:  J Clin Virol       Date:  2013-10-18       Impact factor: 3.168

6.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.

Authors:  Lara F Bratcher; Vikrant V Sahasrabuddhe
Journal:  Infect Agent Cancer       Date:  2010-05-12       Impact factor: 2.965

7.  Paradoxes in dermatology.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian Dermatol Online J       Date:  2013-04

8.  Mucosal and cutaneous human papillomaviruses detected in raw sewages.

Authors:  Giuseppina La Rosa; Marta Fratini; Luisa Accardi; Graziana D'Oro; Simonetta Della Libera; Michele Muscillo; Paola Di Bonito
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

Review 9.  HPV Carcinomas in Immunocompromised Patients.

Authors:  Nicole M Reusser; Christopher Downing; Jacqueline Guidry; Stephen K Tyring
Journal:  J Clin Med       Date:  2015-01-29       Impact factor: 4.241

10.  Diagnosis of HIV-Associated Oral Lesions in Relation to Early versus Delayed Antiretroviral Therapy: Results from the CIPRA HT001 Trial.

Authors:  Ashita S Batavia; Rode Secours; Patrice Espinosa; Marc Antoine Jean Juste; Patrice Severe; Jean William Pape; Daniel W Fitzgerald
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.